Major Pharma Companies Including AstraZeneca and Eli Lilly Announce Leadership Restructuring Amid Strategic Shifts in China

　　【Pharmaceutical Network Industry Dynamics】The year 2024 has just begun, and the pharmaceutical industry is already undergoing major personnel adjustments. Among them, multinational pharmaceutical companies such as AstraZeneca, Eli Lilly, and Pfizer, as well as local Chinese pharmaceutical enterprises, have all been refreshing their senior management structures.
 

From the perspective of large multinational pharmaceutical companies, AstraZeneca announced organizational restructuring and senior management changes on January 12: First, the establishment of a biopharmaceutical business in China, to be led by Lin Xiao; Second, Chen Kangwei, the current General Manager of AstraZeneca China's Oncology Division, will return to Singapore for family reasons and has been appointed as the head of AstraZeneca's commercial operations in Asia. This position will now be concurrently held by Lai Minglong, General Manager of AstraZeneca China.
 

Regarding the continuous adjustments to its structure, AstraZeneca has stated that the new layout will add momentum to the long-term development of its business. According to AstraZeneca's performance report for the first three quarters of 2023, in the biopharmaceutical field, AstraZeneca, led by Farxiga (Dapagliflozin), has achieved extensive coverage in chronic kidney disease, heart failure, and hypertension. After the establishment of the new business, AstraZeneca may be able to plan the development of this field in a more focused and professional manner.
 

The industry indicated that, in response to the ever-changing macro environment and emergencies, AstraZeneca has made a series of structural adjustments in recent years, which also reveals a set of information: AstraZeneca China is actively embracing the domestic market and implementing a strategic transformation of its business in China.
 

In addition to AstraZeneca, on January 9, Eli Lilly announced that Huzur Devletsah would assume the role of President and General Manager of Eli Lilly China. According to information disclosed by Eli Lilly China, Huzur is Turkish and joined Eli Lilly in 1998. Prior to her appointment in China, she served as the President and General Manager for Eli Lilly in Italy, Central and Eastern Europe, Russia and the CIS, as well as Israel. As introduced by Eli Lilly China, during her five-year tenure as the President and General Manager of Eli Lilly in Italy, Central and Eastern Europe, Russia and the CIS, and Israel, Huzur facilitated the launch of major new products across 21 different regions.
 

Data shows that currently, Eli Lilly's business in China covers multiple areas such as diabetes, oncology, immunology, pain, and neurodegenerative diseases. However, in the past two years, Eli Lilly China's performance has not been outstanding among multinational pharmaceutical companies. Statistics indicate that in 2022, Eli Lilly's revenue in China was $1.453 billion, a year-on-year decrease of 13%. The 2023 half-year report shows that Eli Lilly's revenue in China was $772 million, a year-on-year decrease of 3%. It is reported that Huzur, who previously served as the head of Eli Lilly's International Diabetes Division, will take charge in China. Whether she can accelerate the launch of blockbuster diabetes products like GLP-1 drugs after assuming her new role is highly anticipated.
 

Moreover, on January 9, the new appointment of General Manager of Pfizer China's Oncology Division, Wang Yu, also took effect. This transfer is derived from Pfizer's global restructuring plan announced last year, which established a new Oncology Division to integrate the commercialization and R&D operations in oncology. Under the new structure, Wang Yu will be fully responsible for the strategic planning and overall operation of the oncology business.
 

In addition to multinational pharmaceutical companies, many local pharmaceutical companies have also experienced significant personnel changes recently. On January 12, Junshi Biosciences announced that Mr. NING LI (Li Ning) and Ms. Zou Jianjun assumed new positions. After the qualification review by the Nomination Committee of the company's third Board of Directors, the Board elected Mr. NING LI (Li Ning) as the Vice Chairman of the third Board of Directors and as the Chairman of TopAlliance Biosciences Co., Ltd., the wholly-owned subsidiary, responsible for the company’s overseas business. The Board also agreed to appoint Ms. Zou Jianjun as the General Manager and Chief Executive Officer of the company, responsible for overseeing all operations.
 

According to reports, Mr. Ning Li and Ms. Jianjun Zou achieved outstanding results before taking up their new positions: they accomplished the milestone event of the successful U.S. launch of Toripalimab, a China-produced PD-1 monoclonal antibody, leveraging their extensive FDA review and clinical experience, and established a global commercialization network.
 

Another example is on January 8, Asieris announced the establishment of its Women's Health Division, appointing Cao Shaohua as the head of the division and Senior Vice President of Asieris. In addition, adjustments were made in January to positions such as Vice President of China Resources Double-Crane, Executive President of Fosun Pharma, two independent directors of Jiangzhong Pharmaceutical, General Manager of Changyao Holdings, Chairman of City Pharmaceutical, and Vice General Manager of Shengao Pharmaceutical.
 

Analysts point out that currently, the global biopharmaceutical market is still in a transitional period of fluctuating conditions. Meanwhile, China's pharmaceutical industry, through continuous upgrading, is witnessing accelerated new drug approvals and increasingly improved regulations. Against this backdrop, both large multinational pharmaceutical companies and domestic Chinese firms have no choice but to redefine their strategic positioning in China, adjusting relevant business unit structures, pipelines, and personnel to better embrace new opportunities and challenges.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.